A report says President Trump plans to fire FDA Commissioner Marty Makary, potentially ending his turbulent tenure marked by sharp policy disputes and unusual turnover. The Wall Street Journal cited sources, adding that the move is not finalized and could change. Makary has faced criticism around drug review predictability and has drawn political attention connected to regulatory decisions spanning vaping authorization and other public health controversies. The FDA has also seen repeated senior leadership departures during his time in the role. For the biotech industry, commissioner-level disruption can affect near-term regulatory cadence, agency priorities and the practical interpretation of policy guidance across CDER and CBER—especially as novel modalities continue to move through the pipeline.